Warnes A, Fooks A R
Centre for Applied Microbiology and Research, Porton Down, UK.
Methods Mol Med. 1996;4:33-45. doi: 10.1385/0-89603-334-1:33.
Since the use of molecular biology and genetic engineering techniques has become widespread, a new generation of candidate vaccines has been developed, including live viral vectors (1, 2). The basis of using recombinant viruses as potential vaccines involves the incorporation of specific genes from a pathogenic organism into the genome of a nonpathogenic or attenuated virus. The recombinant virus can then infect specific eukaryotic cells either in vivo or in vitro, and cause them to express the recombinant protein. In our laboratory, successful results have been obtained using replication-deficient recombinant adenoviruses as immunizing agents for tick-borne encephalitis virus NSl protein (3) and measles virus nucleoprotein (4), both of which elicit a protective immune response.
由于分子生物学和基因工程技术的应用已广泛普及，新一代候选疫苗得以开发，其中包括活病毒载体（1, 2）。将重组病毒用作潜在疫苗的基础是把致病生物体的特定基因整合到非致病或减毒病毒的基因组中。然后，重组病毒可在体内或体外感染特定的真核细胞，并使其表达重组蛋白。在我们实验室，使用复制缺陷型重组腺病毒作为蜱传脑炎病毒NSl蛋白（3）和麻疹病毒核蛋白（4）的免疫剂已取得成功结果，这两种蛋白均可引发保护性免疫反应。
